Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD44 | P16070 | 2/20 | 0.45 |
| ▸ | PNMT | P11086 | 2/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | RYR2 | Q92736 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 3/20 | 0.35 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.34 |
| ▸ | OXTR | P30559 | 1/20 | 0.33 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5849050 | 0.98 | CD44 (0.44) | CD44PNMTMAOBRYR2HTR2C | |
| SCHEMBL27080190 | 0.75 | PNMT (0.50) | PNMTHTR2C | |
| SCHEMBL28463524 | 0.75 | PNMT (0.50) | PNMTHTR2C | |
| SCHEMBL31332153 | 0.75 | CHRNB2 (0.41) | HTR2C | |
| SCHEMBL28438076 | 0.75 | PNMT (0.50) | PNMTHTR2C | |
| SCHEMBL31332057 | 0.75 | CHRNB2 (0.41) | HTR2C | |
| SCHEMBL31332409 | 0.74 | PNMT (0.36) | CD44PNMTMAOBRYR2 | |
| SCHEMBL31332380 | 0.73 | SLC40A1 (0.31) | MEN1KMT2A | |
| SCHEMBL61667 | 0.73 | CA1 (0.47) | PLCG1MEN1KMT2ANOX1 | |
| SCHEMBL30533792 | 0.73 | CA1 (0.47) | PLCG1MEN1KMT2ANOX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025011580-A1 | COMPOUND FOR TREATING AND PREVENTING RESPIRATORY SYNCYTIAL VIRUS INFECTION DISEASES | 石药集团中奇制药技术（石家庄）有限公司 | 2025-01-16 | — | — | WO | disclosed |
| CN-119285628-A | Compounds for the treatment and prophylaxis of respiratory syncytial virus infection diseases | 石药集团中奇制药技术（石家庄）有限公司 | 2025-01-10 | — | — | CN | disclosed |
| CN-118852149-A | Compound for treating or preventing RSV virus diseases | 石药集团中奇制药技术（石家庄）有限公司 | 2024-10-29 | — | — | CN | disclosed |
| CN-109879837-B | Methods of preparing compounds for preventing and treating RSV | 上海爱科百发生物医药技术股份有限公司 | 2023-06-09 | — | — | CN | disclosed |
| US-RE49481-E1 | Compounds for the treatment and prophylaxis of respiratory syncytial virus disease | HOFFMANN-LA ROCHE INC. (US) | 2023-04-04 | — | — | US | disclosed |
| US-RE49481-E1 | Compounds for the treatment and prophylaxis of respiratory syncytial virus disease | HOFFMANN-LA ROCHE INC. (US) | 2023-04-04 | — | — | US | disclosed |
| CN-111574475-B | Preparation method of halogenated benzothiepin oxide, product prepared by preparation method and application of product | 西安都创医药科技有限公司 | 2022-09-20 | — | — | CN | disclosed |
| WO-2021147947-A1 | SYNTHESIS AND USE OF CLASS OF RESPIRATORY SYNCYTIAL VIRUS INHIBITORS | 苏州爱科百发生物医药技术有限公司 | 2021-07-29 | — | — | WO | disclosed |
| WO-2021050612-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF RESPIRATORY SYNCYTIAL VIRUS | CIDARA THERAPEUTICS, INC. (US) | 2021-03-18 | — | — | WO | disclosed |
| CN-111574475-A | Preparation method of halogenated benzothiepin oxide, product prepared by preparation method and application of product | 西安都创医药科技有限公司 | 2020-08-25 | — | — | CN | disclosed |
| US-20130090328-A1 | COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS DISEASE | Hoffmann-La Roche Inc (US) | 2013-04-11 | — | — | US | disclosed |
| US-20130090328-A1 | COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS DISEASE | Hoffmann-La Roche Inc (US) | 2013-04-11 | — | — | US | disclosed |
| EP-2563122-A1 | CHEMICAL COMPOUNDS | Glaxosmithkline LLC (US) | 2013-03-06 | — | — | EP | disclosed |
| WO-2013020993-A1 | COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2013-02-14 | — | — | WO | disclosed |
| WO-2013020993-A1 | COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2013-02-14 | — | — | WO | disclosed |
| WO-2011137135-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2011-11-03 | — | — | WO | disclosed |
| US-7312208-B2 | Quaternary ammonium compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2007-12-25 | — | — | US | disclosed |
| CN-1027505-C | Process for preparing benzoheterocyclic compounds | OTSUKA PHARMA CO LTD (JP) | 1995-01-25 | — | — | CN | disclosed |
| EP-0626952-A1 | HYPOLIPIDAEMIC BENZOTHIAZEPINE COMPOUNDS | THE WELLCOME FOUNDATION LIMITED (GB) | 1994-12-07 | — | — | EP | disclosed |
| WO-1993016055-A1 | HYPOLIPIDAEMIC BENZOTHIAZEPINE COMPOUNDS | THE WELLCOME FOUNDATION LIMITED (GB) | 1993-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130090328-A1 | COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS DISEASE | XDH, RNASEH1, SUCNR1 | CD44 2342/4885PNMT 3908/4885MAOB 1287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.